Novartisā recent dual clinical setbacks have prompted questions from a major shareholder about the boardās oversight of dealmaking. | Novartisā recent dual clinical setbacks have prompted questions from a major shareholder about the boardās oversight of dealmā¦
FiercePharma
September 10, 2026 ⢠14:26
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters - Fierce Pharma
By Angus Liu